

Ref: Syn/CS/SE/Reg 30/2022-23/Aug/05

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India

T +91 80 6891 8000 **F** +91 80 6775 8808

CIN: L85110KA1993PLC01493

August 10, 2022 <u>www.syngeneintl.com</u>

To,	To,
The Manager,	The Manager,
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

<u>Subject: Intimation of incorporation of a wholly owned subsidiary of Syngene International Limited</u> - Syngene Scientific Solutions Limited

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(SEBI Listing Regulations), , we wish to inform you that Syngene Scientific Solutions Limited ("SSSL")., a wholly-owned subsidiary company of the Company has been incorporated on August 10, 2022 under corporate identification number U73200KA2022PLC164804.

The details in respect of SSSL, as required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided in the enclosed Annexure.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

We request you to kindly take same on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Priyadarshini Mahapatra

Company Secretary and Compliance Officer



Annexure

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover, etc.	Name: Syngene Scientific Solutions Limited ("SSSL")
		Authorised Capital: 5,00,00,000 equity shares of Rs. 10 /- each aggregating to Rs. 50,00,00,000/-
		Subscribed Capital: 10,00,000 equity shares of Rs. 10 /- each aggregating to Rs. 1,00,00,000/-
		Turnover – Not applicable as it is a newly incorporated Company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity	SSSL will be a related party of Syngene International Limited as it has been incorporated as a wholly owned subsidiary
	being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	The Promoters / promoter group / group companies are not interested in the transaction.
3	Industry to which the entity being acquired belongs.	Scientific Research and Development
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	SSSL shall be engaged in Contract Research and Manufacturing Services (CRAMS) and Clinical research services.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition.	Not Applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash
8	Cost of acquisition or the price at which the shares are acquired.	10,00,000 equity shares of Rs. 10/- each aggregating to Rs. 1,00,00,000/-
9	Percentage of shareholding /control acquired and/ or number of shares acquired.	100 per cent
10	Brief background about the entity acquired in terms of products/line of business	Syngene Scientific Solutions Limited is a public company incorporated on August

Syn	gene
-----	------

Sr. No.	Particulars	Details
	acquired, date of incorporation, history of	10, 2022 under the provisions of the
	last 3 years turnover, country in which the	Companies Act, 2013, under the CIN-
	acquired entity has presence and any other	U73200KA2022PLC164804, having its
	significant information (in brief).	registered office in the State of Karnataka.
		SSSL shall be engaged in Contract Research
		and Manufacturing Services (CRAMS) and
		Clinical research services.